SCHEMBL2063370

SCHEMBL2063370

COc1cc2c(Nc3ccc4[nH]ccc4c3)ccnc2cc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.56
PDGFRA P16234 1/20 0.50
ERBB2 P04626 1/20 0.49
GAK O14976 5/20 0.49
SRC P12931 2/20 0.49
RIPK2 O43353 2/20 0.49
COQ8A Q8NI60 2/20 0.49
NLK Q9UBE8 2/20 0.49
BMPR1B O00238 1/20 0.49
EPHB6 O15197 1/20 0.49
ABL1 P00519 1/20 0.49
LCK P06239 1/20 0.49
EPHA1 P21709 1/20 0.49
EPHA8 P29322 1/20 0.49
ACVR1 Q04771 1/20 0.49
MAP2K5 Q13163 1/20 0.49
RAF1 P04049 2/20 0.48
BRAF P15056 2/20 0.48
RET P07949 1/20 0.47
JAK2 O60674 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030630 0.92 RET (0.58) EGFRPDGFRAGAKSRCRIPK2
SCHEMBL4383397 0.83 RET (0.70) EGFRERBB2GAKRIPK2LCK
Hydrochloric Acid SCHEMBL4377353 0.82 RET (0.69) EGFRERBB2GAKRIPK2LCK
SCHEMBL2063817 0.81 EGFR (0.55) EGFRPDGFRAERBB2GAKSRC
SCHEMBL2063094 0.80 EGFR (0.53) EGFRPDGFRAERBB2GAKSRC
SCHEMBL2062952 0.79 EGFR (0.52) EGFRPDGFRAERBB2GAKSRC
SCHEMBL28872407 0.78 PDGFRB (0.54) EGFRPDGFRAABL1LCKKDR
SCHEMBL2063088 0.78 EGFR (0.48) EGFRPDGFRAERBB2GAKSRC
SCHEMBL30791018 0.76 MAPT (0.61) EGFRGAKSRCFLT1KDR
SCHEMBL28968031 0.76 MAPT (0.61) EGFRGAKSRCFLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020020190-A1 METHOD FOR SYNTHESIZING QUINOLINE DERIVATIVE 正大天晴药业集团股份有限公司 2020-01-30 WO disclosed
EP-2125776-B1 SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS ADVENCHEN LABORATORIES LLC (US) 2017-07-05 EP disclosed
US-8148532-B2 Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases CHEN GUOQING PAUL (US) 2012-04-03 US disclosed
EP-2125776-A1 SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS Advenchen Laboratories, LLC (US) 2009-12-02 EP disclosed
WO-2008112407-A1 SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS ADVENCHEN LABORATORIES, LLC (US) 2008-09-18 WO disclosed
US-20080227811-A1 Spiro Substituted Compounds As Angiogenesis Inhibitors ADVENCHEN LABORATORIES, LLC 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227811-A1 Spiro Substituted Compounds As Angiogenesis Inhibitors TEK, KDR, TIE1 EGFR 54/4885PDGFRA 8/4885ERBB2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.